公开(公告)号：US20110009368A1

公开(公告)日：2011-01-13

申请号：US12747234

申请日：2008-12-11

Applicant: Evanthia Dova

Inventor： Evanthia Dova

IPC: A61K31/675 ,  C07F9/6561 ,  A61P31/18

CPC classification number: C07F9/65616 ,  C07C51/412 ,  C07C55/10 ,  C07C59/255 ,  C07C59/265 ,  C07C59/285 ,  C07C65/10

Abstract: The Present Invention Provides Tenofovir Disoproxil Succinate, Tenofovir Disoproxil L-Tartrate, Tenofovir Disoproxil oxalate, Tenofovir disoproxil saccharate, Tenofovir disoproxil citrate, Tenofovir disoproxil salicylate and various solid forms thereof, methods for the preparation thereof and their use in pharmaceutical applications, in particular in anti-HIV medicaments. The forms of Tenofovir disoproxil can be used in combination with other anti-HIV medicaments such as Efavirenz and Emtricitabine.

Abstract translation: 本发明提供了替诺福韦组合物，替诺福韦酯，盐酸替诺福韦酯，替诺福韦酯，草酸替诺福韦酯，柠檬酸替诺福韦酯，水杨酸替诺福韦酯，各种固体形式，其制备方法及其在制药应用中的用途， 抗艾滋病毒药物。 替诺福韦组合的替诺福韦可与其他抗艾滋病药物如依法韦仑和恩曲他滨联合使用。

公开(公告)号：US20110288045A1

公开(公告)日：2011-11-24

申请号：US13129676

申请日：2009-11-19

Applicant: Rita Ramos ,  Evanthia Dova ,  Samir Kulkarni ,  Marcel Hoffmann

Inventor： Rita Ramos ,  Evanthia Dova ,  Samir Kulkarni ,  Marcel Hoffmann

IPC: A61K31/7068 ,  A61P31/18 ,  A61P31/12

CPC classification number: A61K9/1652 ,  A61K9/2054 ,  A61K31/513 ,  A61K31/536 ,  A61K31/675 ,  A61K2300/00

Abstract: The present invention describes a method and composition for a pharmaceutical product based on Tenofovir disoproxil hemifumarate, Emtricitabine and Efavirenz. The composition can be prepared by a process comprising a wet granulation step to produce a stable dosage form suitable for the treatment of HIV in essential absence of known degradation products.

Abstract translation: 本发明描述了一种基于替诺福韦替夫昔伐半富马酸盐，恩曲他滨和依法韦仑的药物产品的方法和组合物。 组合物可以通过包括湿法制粒步骤的方法制备，以产生适合于在已知降解产物基本不存在下治疗HIV的稳定剂型。

公开(公告)号：US20090270352A1

公开(公告)日：2009-10-29

申请号：US12301872

申请日：2008-05-21

Applicant: Evanthia Dova ,  Jaroslaw Marek Mazurek ,  Johnny Anker

Inventor： Evanthia Dova ,  Jaroslaw Marek Mazurek ,  Johnny Anker

IPC: A61K31/675 ,  A61P31/18 ,  C07D473/00

CPC classification number: C07F9/65616 ,  A61K31/675

Abstract: The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114.

Abstract translation: 本发明提供了一种新型的替诺福韦替洛昔韦富马酸（Tenofovir DF）的结晶形式，称为Co-crystal TDFA 2：1，其制备方法及其在药物应用中的用途，特别是抗HIV药物中的应用。 结晶形式TDFA 2：1可以与其他抗艾滋病毒药物如依法韦仑，依曲他滨，利托那韦和/或TMC114组合使用。

公开(公告)号：US20090176983A1

公开(公告)日：2009-07-09

申请号：US12325525

申请日：2008-12-01

Applicant: Evanthia Dova ,  Jaroslaw Marek Mazurek ,  Johnny Anker

Inventor： Evanthia Dova ,  Jaroslaw Marek Mazurek ,  Johnny Anker

IPC: C07D239/70

CPC classification number: C07F9/65616 ,  A61K31/675

Abstract: The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114.